35597-43-4|Bilanafos|(2-amino-4-((hydroxymethyl)hydrophosphoryl)butanoyl)-L-alanyl-L-alanine|-范德生物科技公司

Bilanafos

NMR下载 COA and HPLC MSDS下载
names：
(2-amino-4-((hydroxymethyl)hydrophosphoryl)butanoyl)-L-alanyl-L-alanine
CAS号：
35597-43-4
MDL Number：
MF(分子式)： C11H22N3O6P MW(分子量)： 323.28
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK12646-100mg	100mg	>98%	¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Bilanafos
英文别名	Bilanafos; Bialaphos; Herby; Antibiotic SF 1293;
CAS号	35597-43-4
Inchi	InChI=1S/C11H22N3O6P/c1-6(9(16)14-7(2)11(18)19)13-10(17)8(12)3-4-21(20)5-15/h6-8,15,21H,3-5,12H2,1-2H3,(H,13,17)(H,14,16)(H,18,19)/t6-,7-,8?/m0/s1
InchiKey	VGEZOZJJXPKDEJ-WPZUCAASSA-N
分子式 Formula	C11H22N3O6P
分子量 Molecular Weight	323.28
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Bilanafos(CAS:35597-43-4):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Bilanafos is an Anti-Bacterial Agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Bilanakis N, Vratsista A, Siorou S. A brain ependymoma with psychiatric manifestation. J BUON. 2017 Nov-Dec;22(6):1604-1605. PubMed PMID: 29332363.

[2]Bilanakis N, Peritogiannis VK, Vratsista A. Treatment decision-making capacity in hospitalized patients with schizophrenia. Psychiatriki. 2017 Jan-Mar;28(1):37-45. doi: 10.22365/jpsych.2017.281.37. PubMed PMID: 28541237.

[3] Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, Bitter I, Bilanakis N, Schreiner A. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016 Jun;17(8):1043-53. doi: 10.1080/14656566.2016.1174692. Epub 2016 May 9. PubMed PMID: 27042990; PubMed Central PMCID: PMC4898156.

[4] Bilanakis N, Vratsista A, Athanasiou E, Niakas D, Peritogiannis V. Medical patients' treatment decision making capacity: a report from a general hospital in Greece. Clin Pract Epidemiol Ment Health. 2014 Nov 26;10:133-9. doi: 10.2174/1745017901410010133. eCollection 2014. PubMed PMID: 25505489; PubMed Central PMCID: PMC4260233.

[5] Bilanakis N, Vratsista A, Kalampokis G, Papamichael G, Peritogiannis V. The Greek version of the MacArthur competence assessment tool for treatment: reliability and validity. Evaluation of capacity for treatment decisions in Greek psychiatric patients. Ann Gen Psychiatry. 2013 Apr 9;12(1):10. doi: 10.1186/1744-859X-12-10. PubMed PMID: 23570333; PubMed Central PMCID: PMC3648422.

6: Bilanakis N. [Compulsory hospitalization: α case of conflict between the psychiatrist and the persecutor due to the obscurity of the law]. Psychiatriki. 2012 Jul-Sep;23(3):255-61. Greek, Modern. PubMed PMID: 23073548.7: Bilanakis N, Papamichael G, Peritogiannis V. Chemical restraint in routine clinical practice: a report from a general hospital psychiatric ward in Greece. Ann Gen Psychiatry. 2011 Feb 24;10:4. doi: 10.1186/1744-859X-10-4. PubMed PMID: 21349171; PubMed Central PMCID: PMC3050779.8: Bilanakis N, Kalampokis G, Christou K, Peritogiannis V. Use of coercive physical measures in a psychiatric ward of a general hospital in Greece. Int J Soc Psychiatry. 2010 Jul;56(4):402-11. doi: 10.1177/0020764009106620. Epub 2009 Jul 23. PubMed PMID: 19628555.9: Bilanakis N, Peritogiannis V. Attitudes of patients and families toward restraint and seclusion. Psychiatr Serv. 2008 Oct;59(10):1220. doi: 10.1176/appi.ps.59.10.1220. PubMed PMID: 18832516.10: Bilanakis N, Peritogiannis V, Kalampokis G. Infections as complications of neuroleptic malignant syndrome. World J Biol Psychiatry. 2009;10(4 Pt 3):973-6. doi: 10.1080/15622970801935578. PubMed PMID: 18609425.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开